In this study, we want to learn about a new tool that helps cancer patients make decisions. We also want to understand how patients and doctors communicate when choosing treatments.

Do you have a cancer that is advanced or metastatic? Has your cancer progressed on other standard of care therapies? If you answered yes, then this research study may be for you. Study drug will be provided

We know multiple myeloma can take a long time to diagnose. In this study, we want to better understand how your myeloma was diagnosed so we can identify ways to improve the process.

In this study, we want to help Black and African American people who have had colon cancer, rectal cancer, or colorectal cancer. We want to see if an exercise program can help with cancer side effects and overall quality of life.

In this study, we will find out if a new experimental pill called ropidoxuridine can help improve the treatment of a brain cancer called IDH-Wildtype Glioblastoma. We want to see how well it works when used with radiation therapy.

Do you have relapsed peripheral T-cell lymphoma (PTCL)? Has your cancer not gotten better with other treatments, or were those treatments stopped because of bad side effects? If so, you might be able to join a study to see if a new drug called Soquelitinib (also known as CPI-818) can treat PTCL better.

This study is being carried out to learn more about administration of xaluritamig in people with high-risk biochemical recurrence (BCR) or sometimes referred to as nonmetastatic castration-sensitive prostate cancer (nmCSPC) after receiving definitive (primary) treatment.

Do you have advanced melanoma that has progressed on treatment? Do you have a tumor longer than 1cm in length? If so, you might be able to take part in a study that compares a study treatment (Vusolimogene Oderparepvec and Nivolumab) with your physician's choice of standard of care treatment. Compensation provided.

Have you been diagnosed with hormone receptor (HR+) and human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer? If so, you may be eligible for a clinical trial investigating the combination of endocrine therapy with alisertib.

Have you been diagnosed with cancer. If so, you may be able to take part in a research study looking to improve cancer care for patients whose treatment outcomes have led to challenges in their quality of life.